{"entity":{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","aka":[],"tldr":"A same-day PET tracer could replace the two-day, low-resolution MIBG scan children now undergo repeatedly.","summary":"Children with neuroblastoma repeatedly undergo 123I-MIBG scintigraphy, a two-day, low-resolution scan, and this idea proposes replacing it with same-day 18F-MFBG PET. 18F-meta-fluorobenzylguanidine uses the same norepinephrine-transporter biology as MIBG but gains PET resolution and 18F logistics, needs no sedation across two days, and early data show higher lesion detection. The hypothesis is that MFBG PET/CT detects more lesions than MIBG SPECT with equal specificity, and that Curie-type scoring on MFBG predicts outcome at least as well. Prospective paired comparisons are under way at MSK and in COG imaging studies and an NDA is in progress; at an early clinical stage, it sits within the paediatric oncology roadmap alongside the MIBG theranostics and PET records.","asOf":"2026-09-07","links":[{"label":"Pandit-Taskar et al., Biodistribution and dosimetry of 18F-meta-fluorobenzylguanidine: a first-in-human PET study (Journal of Nuclear Medicine 2017)","url":"https://doi.org/10.2967/jnumed.117.193169"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["mibg-theranostics","pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-pandit-taskar-j-nucl-med"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"18F-MFBG PET/CT detects more lesions than 123I-MIBG SPECT with equal specificity, and Curie-type scoring on MFBG predicts outcome at least as well.","rationale":"MFBG uses the same norepinephrine-transporter biology as MIBG but with PET resolution and 18F logistics.","test":"Paired prospective comparison in newly diagnosed and relapsed patients; response prediction analysis.","maturity":"early-clinical"},"route":"/ideas/idea-mfbg-pet-replaces-mibg/","neighbours":{"cancer":[{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"technology":[{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/"},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"}],"paper":[{"id":"paper-pandit-taskar-j-nucl-med","kind":"paper","name":"Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies","route":"/key-papers/paper-pandit-taskar-j-nucl-med/"}],"roadmap":[{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/"}]}}